IO Biotech, Inc. (IOBTQ): Nasdaq/NYSE listing notice — IO Biotech receives Nasdaq bid price deficiency notice; stock at risk of delisting

IO Biotech, Inc.

Nasdaq notice on Dec 26, 2024: common stock bid price below $1.00 for 30 consecutive days.
Company has 180 days, until June 24, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.
Failure to comply could lead to delisting; may qualify for additional 180-day period if transferred to Nasdaq Capital Market.
No immediate effect on listing; trading continues on Nasdaq Global Select Market pending compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 26, 2024, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s commo

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-285936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.